IP Library Granted Patent US 10,695,421
Granted Patent B2
US 10,695,421 · App. 16/267,454 · Granted Jun 30, 2020

Nucleic acid molecule encoding hepatitis B virus core protein and vaccine comprising the same

Inventors: David Weiner (Merion, PA); Jian Yan (Wallingford, PA); Nyamekye Obeng-Adjei (Lansdowne, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K39/292A61K39/12A61K39/39A61P31/20C07K14/005C07K14/02C12N7/00A61K2039/53A61K2039/57A61K2039/572C12N2730/10134C12N2730/10171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,695,421
App. No.
16/267,454
Granted
Jun 30, 2020
Kind
B2
Abstract

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HBV core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against HBV using the nucleic acid sequences that are provided.

Claims (9)

1. An immunogenic composition comprising a nucleic acid molecule encoding an immunogenic fragment of a consensus hepatitis B virus (HBV) core protein that comprises at least 50% of the full length of SEQ ID NO:2, wherein the immunogenic fragment comprises serine residues at amino acids 74 and 87 of SEQ ID NO:2.

2. The immunogenic composition of claim 1 , wherein the nucleic acid molecule comprises a nucleic acid sequence encoding a signal peptide linked to the immunogenic fragment of SEQ ID NO: 2.

3. The immunogenic composition of claim 1 comprising a nucleic acid fragment of SEQ ID NO:1 that comprises at least 50% of the full length of SEQ ID NO:1.

4. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is a plasmid.

5. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is an expression vector.

6. The immunogenic composition of claim 1 , wherein the nucleic acid molecule is incorporated into a viral particle.

7. The immunogenic composition of claim 1 further comprising an adjuvant molecule.

8. The immunogenic composition of claim 7 , wherein the adjuvant is IL-12, IL-15, IL-28, or RANTES.

9. A method of inducing an immune response against HBV comprising administering the immunogenic composition of claim 1 to a subject.

Continuity (4)
Continuation 15213747 · Jul 19, 2016
Continuation 13984771
Provisional Application 61442162 · Feb 11, 2011
Related Publication 20190151443A1 · May 23, 2019
Cited By (1)
US 12,364,751